Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 100%High 0 · 0%

Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1114 participants
Moderate

Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1132 participants
Moderate

Difference in mean IOP from baseline at < 6 months · people with primary open‐angle glaucoma or ocular hypertension

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1283 participants
Moderate